Lipella Pharmaceuticals Inc. (LIPO)
Lipella Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Pittsburgh, PA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $924. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 1.56 implies it has historically moved more than the broad market.
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc. is most often compared with the following Healthcare names: